



Zytiga[®] (abiraterone acetate) – First-time generic

- On November 23, 2018, Patriot Pharmaceuticals launched an authorized generic version of Janssen's [Zytiga \(abiraterone acetate\)](#) 250 mg tablets.
 - Apotex, Hikma, Mylan, and Teva also launched AB-rated generic versions of Zytiga 250 mg tablets.
 - Janssen [plans to pursue](#) an injunction against the “at-risk” launch from the various generic manufacturers.
- Zytiga is approved for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer.
- Brand Zytiga is also available as 500 mg tablets. In addition, abiraterone acetate is available as the branded product, [Yonsa[®]](#).
 - Yonsa is approved for use in combination with methylprednisolone for the treatment of patients with metastatic CRPC.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.